|Articles|July 29, 2013

Mechanism of Action: Afatinib (BIBW 2992)

Afatinib is an FDA-approved pan-HER inhibitor for the first-line treatment of patients with metastatic NSCLC whose tumors have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations.

Afatinib (Gilotrif), previously known as BIBW 2992, is an FDA-approved pan-HER inhibitor for the first-line treatment of patients with metastatic non-small cell lung cancer whose tumors have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test.

Stay up to date on practice-changing data in community practice.

Mechanism of Action: Afatinib (BIBW 2992)

Related Content

Why Do Asian American Women Have Better Breast Cancer Survival?

Growing Alcohol-Attributable Cancer Burden in US Reveals Prevention Gap

Expanding Blood Cancer Care With the Next Frontier of T-Cell Immunotherapy

FDA Approves Camizestrant Plus CDK4/6 Inhibitor for ESR1-Mutant Breast Cancer

Azacitidine-Venetoclax Beats Induction Chemo as Upfront AML Therapy

Latest CME

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Rhode Island Oncology Society

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Iowa Oncology Society

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Empire State Hematology & Oncology Society

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | South Carolina Oncology Society

Community Oncology Connections™: How Can We Optimize the Use of Oral SERDs in the Community Oncology Setting? Best Practices for HR+/HER2– Breast Cancer | Texas Society of Clinical Oncology

Satellite Symposia at the Annual Radiation Oncology Meeting

Community Oncology Connections™: How Can We Optimize the Use of Oral SERDs in the Community Oncology Setting? Best Practices for HR+/HER2– Breast Cancer | Tennessee Oncology Practice Society

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Washington State Medical Oncology Society

North Carolina Oncology Association

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Colorado Oncology Society

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Indiana Oncology Society

Washington State Medical Oncology Society

Missouri Oncology Society

New Mexico Society of Clinical Oncology

Nevada Oncology Society

Louisiana Oncology Society

Wyoming State Oncology Society

Montana State Oncology Society

Beyond Primary End Points: Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer

Medical Crossfire®: Mastering the Nuances of Early-Stage HR+/HER2- Breast Cancer—Expert Perspectives on Applying Modern Treatment Paradigms

Medical Crossfire™: Navigating the Expanding Arsenal of Endocrine Therapies for HR+/HER2- Metastatic Breast Cancer – How Can PROTAC ER Degradation Shift the Standard?

Module 4: Breast Surgery (2025)

Module 5: Breast Radiation Therapy (2025)

Module 3: Pathology And Biomarkers (2025)

Module 6: Adjuvant/Neoadjuvant Chemotherapy and Endocrine Therapy (2025)

Module 1: Breast Carcinogenesis & Management of High-Risk Disease (2025)

Module 7: Systemic Treatment Of Advanced/Metastatic Disease (2025)

Module 2: Breast Imaging (2025)

Module 8: Organ-Targeted Treatment of Metastatic Disease (2025)

Module 9: Toxicity Management And Survivorship Considerations (2025)

First-Line ADC Monotherapy in mTNBC: Addressing Unmet Needs in Immunotherapy-Ineligible Populations

Combination Approaches in PD-L1–Positive mTNBC: Practice-Changing Frontline Evidence

Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways

Dr Pant Discusses Next Steps in Daraxonrasib Development for Pancreatic Cancer

Growing Alcohol-Attributable Cancer Burden in US Reveals Prevention Gap

Expanding Blood Cancer Care With the Next Frontier of T-Cell Immunotherapy

AUA/SUO Issue 2026 Update to Non–Muscle Invasive Bladder Cancer Guideline

FDA Approves Camizestrant Plus CDK4/6 Inhibitor for ESR1-Mutant Breast Cancer